Park Medi World Share Price Target Raised To ₹350 By Choice Institutional Equities

May 27, 20263 Mins Read

May 27, 2026 : Park Medi World Ltd is increasingly emerging as one of the fastest-growing healthcare expansion stories in India’s listed hospital space.

Author: Aadarsh Patel | EQMint

In its latest management meet note, Choice Institutional Equities maintained a “BUY” rating on the company and raised the target price to ₹350 from ₹320, implying an upside potential of nearly 22% from current levels.

The brokerage highlighted Park Medi World’s aggressive capacity expansion strategy, operational efficiency and disciplined capital deployment as major growth drivers.

Uttarakhand acquisition becomes major growth trigger

A key highlight was the acquisition of Medicity Hospital in Rudrapur, Uttarakhand, through an all-cash deal worth ₹1,770 million funded entirely via internal accruals.

The acquisition expands the company’s network to 17 hospitals across six states while increasing total bed capacity to around 4,290 beds.

Management expects operations at the acquired hospital to begin by August 2026.

In the first year itself, the company is targeting:

₹1,000 million revenue

₹200 million EBITDA

60–65% occupancy levels

By Year 2, occupancy is expected to rise to 70–75%, supported by higher super-specialty revenue and advanced medical procedures.

Massive expansion roadmap ahead

According to projections in the report, Park Medi World’s total bed capacity could rise to 6,490 by FY29E. Revenue is expected to grow at a CAGR of 32.9% between FY26 and FY29E.

PAT is projected to grow even faster at 39.2% CAGR over the same period.

Despite aggressive expansion, EBITDA margins are expected to remain stable around 26.5%, which analysts view as a major positive.

The company is also focusing on:

oncology expansion in Ambala

super-specialty care in Mohali

robotic and advanced procedures

ARPOB growth through richer case mix

Strong balance sheet adds confidence

One of the biggest positives highlighted in the report is the company’s improving financial position.

Management stated that Park Medi World turned debt-free in February 2026 and continues generating healthy operating cash flows.

The report also projects:

ROCE rising to 25.4% by FY29E

ROE improving to 21.2%

EBITDA crossing ₹10 billion by FY29E

EQMint analysis

Park Medi World is positioning itself differently from premium hospital chains.

Instead of luxury-focused expansion, the company is building a scalable mid-market healthcare network focused on operational efficiency and asset ownership.

That matters because India’s healthcare growth opportunity increasingly lies in affordable tertiary and super-specialty care outside metro cities.

The company’s cluster-based strategy, rising occupancy levels and debt-free balance sheet make the story attractive from a long-term compounding perspective.

However, execution remains the key risk.

Aggressive expansion in healthcare requires consistent doctor availability, occupancy ramp-up and operational integration. If management executes successfully, PARKHOSP could continue commanding premium valuations in the hospital sector.